Skip to main content

Table 3 Patient demographics and clinical characteristics

From: Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment

Patient demographic characteristics

 

Asthma (n = 201)

COPD (n = 93)

Total (n = 294)

Age

Mean (SD)

40.30 (13.44)

48.48 (15.16)

42.89 (14.49)

Gender

Male

63 (31.34%)

42 (45.16%)

105 (35.71%)

Female

138 (68.66%)

51 (54.84%)

189 (64.29%)

Current inhaler

Symbicort Turbuhaler

95 (47%)

44 (47%)

139 (47%)

Seretide Diskus

106 (53%)

49 (53%)

155 (53%)

Revenue in last 12 months

<€22,500

97 (48.26%)

40 (43.01%)

137 (46.60%)

€25,000–€34,999

39 (19.40%)

14 (15.05%)

53 (18.03%)

€35,000–€49,999

30 (14.93%)

15 (16.13%)

45 (15.31%)

€50,000–€74,999

15 (7.46%)

7 (7.53%)

22 (7.48%)

€75,000+

2 (1.00%)

6 (6.45%)

8 (2.72%)

No answer

18 (8.96%)

11 (11.83%)

29 (9.86%)

Costs associated with asthma and COPD treatment (€)/month

Mean (SD)

11.89 (21.93)

22.11 (37.37)

15.12 (28.10)

HUI3

Mean (SD)

0.71 (0.25)

0.54 (0.30)

0.66 (0.28)

  1. COPD chronic obstructive pulmonary disease, DPI dry powder inhaler, HUI3 health utilities index mark III, SD standard deviation